查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566971

结膜炎市场：按类型、疾病类型、最终用户划分：2024-2033 年全球机会分析与产业预测

Conjunctivitis Market By Type , By Disease Type By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 228 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年结膜炎市值为48亿美元，预计2024年至2033年复合年增长率为4.1%，到2033年达到72亿美元。

结膜炎是最常见的眼部感染疾病，会导致结膜（排列在眼白和眼睑内侧的薄而透明的膜）发炎。它可能由多种因素引起，包括病毒和细菌感染、过敏原和刺激物。这种情况的特征是眼睛发红、发痒、肿胀和分泌物。结膜炎通常令人不舒服且具有传染性，但通常是可以治疗的，并且很少引起严重的併发症。

全球结膜炎市场的成长是由结膜炎的高盛行率（特别是在结膜炎频繁发生的地区）以及对治疗和预防措施的需求不断增加所推动的。提供医疗新闻、临床试验报告和药物更新的网站 Medscape 于 2024 年发表的一项研究估计，美国每年将出现 600 万例新发病毒性结膜炎病例。由于污染和花粉等环境因素导致的过敏性结膜炎病例不断增加，推动了对相关治疗的需求。此外，病毒和细菌感染经常发生，特别是在学校和公共运输等拥挤的环境中，增加了对有效治疗方案的需求。此外，由于消费者意识的提高以及无需处方笺即可获得这些产品的便利性，人们对非处方眼部护理产品的偏好增加，也对市场成长做出了重大贡献。此外，老年人口的快速成长也推动了市场的成长。这是因为包括结膜在内的眼组织会自然退化。这使得老年人的眼睛更容易受到刺激、感染和发炎，从而更容易患上结膜炎等疾病。个人化医疗的趋势正在进一步影响结膜炎市场，根据个别患者的情况和结膜炎的具体原因促进客製化治疗。然而，许多人自我诊断结膜炎并使用非处方产品或家用药物进行自我治疗，这可能导致治疗不正确和症状恶化。误诊还会导致不当用药，这是全球市场的一个主要阻碍因素。此外，获得医疗服务和眼科医生的机会有限，阻碍了结膜炎的及时诊断和治疗，导致併发症发生率更高，从而限制了市场成长。相反，药物研究的进步正在导致针对结膜炎的新的、更有效的治疗方法的开发，包括新的抗生素和发炎治疗。此外，将人工智慧和机器学习整合到诊断工具中，以提高结膜炎诊断和治疗计划的准确性和速度，预计将为市场成长提供新的途径。

全球结膜炎市场按类型、疾病类型、最终用户和地区细分。按类型划分，市场分为诊断市场和治疗市场。诊断部分进一步细分为身体检查和临床检查。治疗部分进一步分为抗生素、抗病毒药物、抗过敏药物和人工泪液。根据疾病类型，市场分为过敏性结膜炎、细菌性结膜炎和病毒性结膜炎。过敏性结膜炎又分为季节性过敏性结膜炎和常年性过敏性结膜炎。依最终用户分类，可分为医院和诊所、专业眼科诊所和其他。从区域来看，分析包括北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

按类型划分，治疗细分市场在 2023 年占据最大份额。

按疾病类型划分，过敏性结膜炎细分市场在 2023 年占据主导地位。

从最终用户来看，医院和诊所将在 2023 年成为主要细分市场。

按地区划分，北美是 2023 年结膜炎市场的主要股东，预计在整个预测期内将保持主导地位。

该报告可以定制。

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 历史市场资料
  • 主要参与企业的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第 4 章 联合火焰市场：依类型

  • 市场概况
  • 诊断
    • 体检
    • 临床试验
  • 治疗
    • 抗生素
    • 抗病毒药物
    • 抗过敏剂
    • 人工泪液

第五章综合发炎市场：依疾病类型

  • 市场概况
  • 过敏性结膜炎
    • 季节性过敏性结膜炎
    • 常年性过敏性结膜炎
  • 细菌性结膜炎
  • 病毒性结膜炎

第六章结膜炎市场：依最终用户分类

  • 市场概况
  • 医院和诊所
  • 专业眼科诊所
  • 其他的

第七章思觉失调症发炎市场：按地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国结膜炎市场
    • 加拿大结膜炎市场
    • 墨西哥结膜炎市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国结膜炎市场
    • 法国结膜炎市场
    • 英国结膜炎市场
    • 义大利结膜炎市场
    • 西班牙结膜炎市场
    • 其他欧洲结膜炎市场
  • 亚太地区
    • 主要市场趋势和机会
    • 日本结膜炎市场
    • 中国结膜炎市场
    • 印度结膜炎市场
    • 澳洲结膜炎市场
    • 韩国结膜炎市场
    • 其他亚太结膜炎市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西结膜炎市场
    • 沙特结膜炎市场
    • 南非结膜炎市场
    • 其他拉丁美洲/中东/非洲结膜炎市场

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第九章 公司简介

  • AFT Pharmaceuticals
  • Alembic Pharmaceuticals Ltd
  • Johnson And Johnson Services Inc
  • Ocular Therapeutics, Inc
  • Cipla, Inc.
  • Jabs Biotech Pvt. Ltd.
  • Spectra Vision Care Pvt. Ltd
  • Teva Pharmaceutical Industries Ltd
  • Grevis Pharmaceutical Private Limited
  • Bausch Health Companies Inc
简介目录
Product Code: A324393

The conjunctivitis market was valued at $4.8 billion in 2023, and is projected to reach $7.2 billion by 2033, growing at a CAGR of 4.1% from 2024 to 2033.

Conjunctivitis is the most prevalent eye infection that causes the inflammation of the conjunctiva-the thin, transparent membrane that lines the white part of the eye and the inner surface of the eyelids. It can be caused by various factors, including viral or bacterial infections, allergens, or irritants. This condition is characterized by symptoms such as redness, itching, swelling, and discharge from the eye. While often uncomfortable and contagious, conjunctivitis is typically treatable and rarely causes serious complications.

The growth of the global conjunctivitis market is driven by high prevalence of conjunctivitis, particularly in regions with frequent outbreaks, drives demand for treatment and preventive measures. According to a 2024 study published by Medscape-website providing access to medical news, clinical trial coverage, drug updates-an estimated 6 million new cases of viral conjunctivitis occur annually in the U.S. Increase in cases of allergic conjunctivitis due to environmental factors, such as pollution and pollen, boosts the demand for relevant therapies. Moreover, frequent outbreaks of viral or bacterial infections, especially in crowded settings like schools and public transport, foster the need for effective treatment options. Furthermore, increase in preference for over-the-counter eye care products, driven by increased consumer awareness and the convenience of accessing these products without prescription, notably contributes toward the market growth. In addition, surge in geriatric population propels the market growth. This is attributed to the fact that the tissues in the eyes, including the conjunctiva, undergoes natural degeneration. This makes the eyes of aged individuals more prone to irritation, infections, and inflammation, leading to a higher likelihood of developing conditions like conjunctivitis, which augments the demand for specialized treatments. The trend toward personalized medicine is further impacting the conjunctivitis market by promoting tailored treatments based on individual patient profiles and specific conjunctivitis causes. However, many individuals self-diagnose and self-treat conjunctivitis with over-the-counter products or home remedies, which can lead to incorrect treatment and potential worsening of the condition. Misdiagnosis can also result in inappropriate use of medications, which acts as the key deterrent factor of the global market. In addition, limited access to healthcare services and eye care professionals hinders timely diagnosis and treatment of conjunctivitis, leading to higher rates of complications, thus restraining the market growth. On the contrary, advances in pharmaceutical research are leading to the development of new and more effective therapies, including novel antimicrobial agents and anti-inflammatory treatments for conjunctivitis. Furthermore, integration of AI and ML in diagnostic tools to improve the accuracy and speed of conjunctivitis diagnosis and treatment planning is anticipated to offer new avenues for the market growth.

The global conjunctivitis market is segmented into type, disease type, end user, and region. On the basis of the type, the market is bifurcated into diagnosis and treatment. The diagnosis segment is further segmented into physical examination and laboratory tests. The treatment segment is further classified into antibiotics, antiviral, anti-allergic, and artificial tears. Depending on disease type, the market is divided into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. The allergic conjunctivitis segment is further categorized into seasonal allergic conjunctivitis and perennial allergic conjunctivitis. As per end user, the market is classified into hospitals & clinics, specialty eye clinics, and others. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the treatment segment accounted for the largest share of the market in 2023.

On the basis of disease type, the allergic conjunctivitis segment dominated the market in 2023.

Depending on end user, hospital & clinics emerged as the leading segment in 2023.

Region wise, North America was the major shareholder in the conjunctivitis market in 2023, and is expected to retain its dominance throughout the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global conjunctivitis market include AFT Pharmaceuticals, Alembic Pharmaceuticals Ltd., Johnson & Johnson Services Inc., Ocular Therapeutics, Inc., Cipla, Inc., Jabs Biotech Pvt. Ltd., Spectra Vision Care Pvt. Ltd., Teva Pharmaceutical Industries Ltd., Grevis Pharmaceutical Private Limited, and Bausch Health Companies Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • Diagnosis
    • Physical Examination
    • Laboratory Tests
  • Treatment
    • Antibiotics
    • Antiviral
    • Anti-allergic
    • Artificial Tears

By Disease Type

  • Allergic Conjunctivitis
    • Seasonal Allergic Conjunctivitis
    • Perennial Allergic Conjunctivitis
  • Bacterial Conjunctivitis
  • Viral Conjunctivitis

By End User

  • Hospitals and Clinics
  • Specialty Eye Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • AFT Pharmaceuticals
    • Alembic Pharmaceuticals Ltd
    • Johnson & Johnson Services Inc
    • Ocular Therapeutics, Inc
    • Cipla, Inc.
    • Jabs Biotech Pvt. Ltd.
    • Spectra Vision Care Pvt. Ltd
    • Teva Pharmaceutical Industries Ltd
    • Grevis Pharmaceutical Private Limited
    • Bausch Health Companies Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: CONJUNCTIVITIS MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Diagnosis
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
    • 4.2.5. Physical Examination
      • 4.2.5.1. Market Size and Forecast
    • 4.2.6. Laboratory Tests
      • 4.2.6.1. Market Size and Forecast
  • 4.3. Treatment
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
    • 4.3.5. Antibiotics
      • 4.3.5.1. Market Size and Forecast
    • 4.3.6. Antiviral
      • 4.3.6.1. Market Size and Forecast
    • 4.3.7. Anti-allergic
      • 4.3.7.1. Market Size and Forecast
    • 4.3.8. Artificial Tears
      • 4.3.8.1. Market Size and Forecast

CHAPTER 5: CONJUNCTIVITIS MARKET, BY DISEASE TYPE

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Disease Type
  • 5.2. Allergic Conjunctivitis
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
    • 5.2.5. Seasonal Allergic Conjunctivitis
      • 5.2.5.1. Market Size and Forecast
    • 5.2.6. Perennial Allergic Conjunctivitis
      • 5.2.6.1. Market Size and Forecast
  • 5.3. Bacterial Conjunctivitis
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Viral Conjunctivitis
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: CONJUNCTIVITIS MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Hospitals And Clinics
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Specialty Eye Clinics
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Others
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: CONJUNCTIVITIS MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Type
    • 7.2.3. Market Size and Forecast, By Disease Type
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Conjunctivitis Market
      • 7.2.6.1. Market Size and Forecast, By Type
      • 7.2.6.2. Market Size and Forecast, By Disease Type
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Conjunctivitis Market
      • 7.2.7.1. Market Size and Forecast, By Type
      • 7.2.7.2. Market Size and Forecast, By Disease Type
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Conjunctivitis Market
      • 7.2.8.1. Market Size and Forecast, By Type
      • 7.2.8.2. Market Size and Forecast, By Disease Type
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Type
    • 7.3.3. Market Size and Forecast, By Disease Type
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Conjunctivitis Market
      • 7.3.6.1. Market Size and Forecast, By Type
      • 7.3.6.2. Market Size and Forecast, By Disease Type
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. France Conjunctivitis Market
      • 7.3.7.1. Market Size and Forecast, By Type
      • 7.3.7.2. Market Size and Forecast, By Disease Type
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. UK Conjunctivitis Market
      • 7.3.8.1. Market Size and Forecast, By Type
      • 7.3.8.2. Market Size and Forecast, By Disease Type
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Italy Conjunctivitis Market
      • 7.3.9.1. Market Size and Forecast, By Type
      • 7.3.9.2. Market Size and Forecast, By Disease Type
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. Spain Conjunctivitis Market
      • 7.3.10.1. Market Size and Forecast, By Type
      • 7.3.10.2. Market Size and Forecast, By Disease Type
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Conjunctivitis Market
      • 7.3.11.1. Market Size and Forecast, By Type
      • 7.3.11.2. Market Size and Forecast, By Disease Type
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Type
    • 7.4.3. Market Size and Forecast, By Disease Type
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Conjunctivitis Market
      • 7.4.6.1. Market Size and Forecast, By Type
      • 7.4.6.2. Market Size and Forecast, By Disease Type
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. China Conjunctivitis Market
      • 7.4.7.1. Market Size and Forecast, By Type
      • 7.4.7.2. Market Size and Forecast, By Disease Type
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. India Conjunctivitis Market
      • 7.4.8.1. Market Size and Forecast, By Type
      • 7.4.8.2. Market Size and Forecast, By Disease Type
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. Australia Conjunctivitis Market
      • 7.4.9.1. Market Size and Forecast, By Type
      • 7.4.9.2. Market Size and Forecast, By Disease Type
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. South Korea Conjunctivitis Market
      • 7.4.10.1. Market Size and Forecast, By Type
      • 7.4.10.2. Market Size and Forecast, By Disease Type
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Conjunctivitis Market
      • 7.4.11.1. Market Size and Forecast, By Type
      • 7.4.11.2. Market Size and Forecast, By Disease Type
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Type
    • 7.5.3. Market Size and Forecast, By Disease Type
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Conjunctivitis Market
      • 7.5.6.1. Market Size and Forecast, By Type
      • 7.5.6.2. Market Size and Forecast, By Disease Type
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. Saudi Arabia Conjunctivitis Market
      • 7.5.7.1. Market Size and Forecast, By Type
      • 7.5.7.2. Market Size and Forecast, By Disease Type
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. South Africa Conjunctivitis Market
      • 7.5.8.1. Market Size and Forecast, By Type
      • 7.5.8.2. Market Size and Forecast, By Disease Type
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Conjunctivitis Market
      • 7.5.9.1. Market Size and Forecast, By Type
      • 7.5.9.2. Market Size and Forecast, By Disease Type
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. AFT Pharmaceuticals
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Alembic Pharmaceuticals Ltd
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Johnson And Johnson Services Inc
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Ocular Therapeutics, Inc
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Cipla, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Jabs Biotech Pvt. Ltd.
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Spectra Vision Care Pvt. Ltd
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Teva Pharmaceutical Industries Ltd
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Grevis Pharmaceutical Private Limited
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Bausch Health Companies Inc
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments